Case Report: IL-6 suppression: a potential strategy for mitigating severe immune-related adverse events in nivolumab and ipilimumab therapy for malignant pleural mesothelioma

Our plain-English summary of Case Report: IL-6 suppression: a potential strategy for mitigating severe immune-related adverse events in nivolumab and ipilimumab therapy for malignant pleural mesothelioma, by A. Yanagisawa, T. Fukaya, K. Noda, et al (Frontiers in Oncology, 2025).

The study

• Authors: A. Yanagisawa, T. Fukaya, K. Noda, H. Kojima, H. Shimizu
• Journal: Frontiers in Oncology
• Published: 2025;15:1671503
• Type of article: Case report
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer with a poor prognosis, often presenting challenges in treatment. The CheckMate-743 trial demonstrated significant improvements in overall survival with the combination therapy of nivolumab and ipilimumab in advanced MPM. However, the management of immune-related adverse events (irAEs) remains a critical concern.

Case Presentation: We present a 74-year-old male with a history of polymyalgia rheumatica (PMR), diagnosed two years prior. His PMR was initially treated with corticosteroids, but tapering the dose was difficult. Therefore, tocilizumab was initiated one year before the current presentation, leading to a stable remission. One month before starting cancer therapy, tocilizumab was discontinued while the patient's PMR remained well-controlled. He then developed multiple serious irAEs following the first cycle of nivolumab and ipilimumab for advanced MPM. These included cytokine release syndrome (CRS), immune-related aseptic meningitis, and liver dysfunction. All irAEs were successfully managed with corticosteroids, and the patient's tumor progression remained under control.

Conclusion: This case suggests that residual IL-6 suppression from prior tocilizumab therapy may attenuate the severity of subsequent irAEs, permitting effective management without compromising anti-tumor efficacy. IL-6 modulation could be a promising strategy to improve the therapeutic index of dual checkpoint inhibition in MPM.

Copyright © 2025 Yanagisawa, Fukaya, Noda, Kojima and Shimizu.

In plain English

This case report described one 74-year-old man at a hospital in Tokyo, Japan. He had malignant pleural mesothelioma and a history of asbestos exposure between the ages of 22 and 27. He also had polymyalgia rheumatica, which had been treated with prednisolone and tocilizumab, a drug that blocks the immune signal IL-6. Tocilizumab was stopped. One month later he received one cycle of the drug combination nivolumab and ipilimumab for advanced, unresectable (stage III) mesothelioma. The next day he developed Grade 2 cytokine release syndrome. Ten days after going home he was readmitted with agitation. Doctors diagnosed autoimmune encephalitis, a brain inflammation, and liver injury caused by the two drugs. All of these were controlled with corticosteroids. After that single cycle, his pleural fluid cleared, his tumor shrank, and he stayed stable until day 250. The authors hypothesized that leftover effects of tocilizumab may have made these side effects less severe. They said further studies are needed. The report describes one patient only.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Case report (single patient)
• Who was studied: One 74-year-old man with pre-existing polymyalgia rheumatica, seen at the Department of Respirology, JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan; dates of care not stated
• Exposure: Past asbestos exposure between ages 22 and 27 (fiber type and job not stated). The treatment studied was one cycle of nivolumab plus ipilimumab, given one month after his last dose of tocilizumab.
• Main results:
  • The patient was diagnosed with advanced unresectable malignant pleural mesothelioma, clinical stage cT4N1M0 stage III.
  • The day after the first dose of nivolumab and ipilimumab, he developed fever and low blood pressure, judged consistent with Grade 2 cytokine release syndrome. His IL-6 level was 16.3 pg/ml at onset, compared with 9.5 pg/ml just before treatment.
  • On readmission, the patient was diagnosed with autoimmune encephalitis, an immune-related brain inflammation.
  • He also had marked liver damage (AST 356 U/L, ALT 856 U/L, GTP 862 U/L, ALP 542 U/L), which was diagnosed as drug-induced liver injury due to nivolumab and ipilimumab.
  • The encephalitis was treated with intravenous methylprednisolone 1000 mg/day for 3 days, after which his consciousness and behavior improved.
  • After tocilizumab was reintroduced, no new immune-related adverse events were observed.
  • After a single cycle of immunotherapy, the pleural effusion resolved completely and the solid mesothelioma lesions shrank.
  • The patient remained stable, with no return of pleural effusion or neurological symptoms, until day 250.
• The authors' conclusion: The authors hypothesized that residual effects of tocilizumab, given one month before, may have contributed to the favorable course of the side effects. They concluded that the case highlights a potential role for IL-6 inhibition and that further studies are needed on timing, dosing and integration of IL-6 blockade.
• Limitations the authors state:
  • The authors cautioned that cytokine networks are complex: IL-6 inhibition may trigger compensatory increases in other cytokines such as TNF-a.
  • Only one autoantibody (anti-GAD) was routinely available for testing during the brain work-up.
  • The neurological score, especially the verbal component, was likely influenced by sedation.

Topics

Medical terms in this study, explained in our Lexicon: Immune-Related Adverse Events, Nivolumab (Opdivo), Ipilimumab (Yervoy), Pleural Mesothelioma, Prognosis, Overall Survival, Cytokine.

Related studies

• Partial Response to Nivolumab and Ipilimumab in a Patient With Malignant Pleural Mesothelioma and Pre-Existing Myasthenia Gravis Without Severe Flares or Immune-Related Adverse Events: A Case Report — M. Higa, T. Kuda, et al. (2025)
• Early severe immune-related pneumonitis, hepatitis, and agranulocytosis with radiographic response in sarcomatoid malignant pleural mesothelioma treated with nivolumab and ipilimumab: a case report highlighting dual liver biopsies and rechallenge decision-making — T. Oba, K. Itogawa, et al. (2025)
• Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma — H. Yoneda, H. Nokihara, et al. (2021)
• The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database — H. Yang, Z. Liu, et al. (2023)
• Immune-related adverse events in hepatitis treated with thiopurine-based immunosuppressants: A case report — K. Kawakado, K. Nakashima, et al. (2023)
• Registry study of immune-related adverse events using electronic patient-reported outcome in patients with cancer receiving immune checkpoint inhibitors: protocol for a multicentre cohort study — T. Hirata, T. Kawaguchi, et al. (2023)

Browse more research in Frontiers in Oncology, or return to medical research.